Last reviewed · How we verify
Seasonal influenza vaccine
Seasonal influenza vaccine is a vaccine Biologic drug developed by Novartis. It is currently FDA-approved for Prevention of seasonal influenza in adults and children. Also known as: Agrippal (TM), influenza vaccine 2010 southern hemisphere, lot no 0700302A, Vaxigrip.
The seasonal influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.
The seasonal influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains. Used for Prevention of seasonal influenza in adults and children.
At a glance
| Generic name | Seasonal influenza vaccine |
|---|---|
| Also known as | Agrippal (TM), influenza vaccine 2010 southern hemisphere, lot no 0700302A, Vaxigrip, INTANZA |
| Sponsor | Novartis |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated influenza virus antigens (or live attenuated virus in LAIV formulations) that trigger both humoral and cell-mediated immune responses. This priming allows the immune system to rapidly recognize and neutralize influenza viruses upon natural exposure, reducing infection risk and disease severity. Protection is strain-specific and requires annual reformulation based on predicted circulating strains.
Approved indications
- Prevention of seasonal influenza in adults and children
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Low-grade fever
- Fatigue
Key clinical trials
- A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above (PHASE2)
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants (PHASE3)
- Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- H1ssF Flu Vaccine Clinical Trial (PHASE1)
- Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine (PHASE1, PHASE2)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Seasonal influenza vaccine CI brief — competitive landscape report
- Seasonal influenza vaccine updates RSS · CI watch RSS
- Novartis portfolio CI
Frequently asked questions about Seasonal influenza vaccine
What is Seasonal influenza vaccine?
How does Seasonal influenza vaccine work?
What is Seasonal influenza vaccine used for?
Who makes Seasonal influenza vaccine?
Is Seasonal influenza vaccine also known as anything else?
What drug class is Seasonal influenza vaccine in?
What development phase is Seasonal influenza vaccine in?
What are the side effects of Seasonal influenza vaccine?
Related
- Drug class: All vaccine drugs
- Manufacturer: Novartis — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of seasonal influenza in adults and children
- Also known as: Agrippal (TM), influenza vaccine 2010 southern hemisphere, lot no 0700302A, Vaxigrip, INTANZA
- Compare: Seasonal influenza vaccine vs similar drugs
- Pricing: Seasonal influenza vaccine cost, discount & access